ARCTURUS THERAPEUTICS HOLDINGS INC. Form 8-K (Nov. 10, 2020)

Summary

Current report on Form 8-K of Arcturus Therapeutics Holdings Inc., date of report November 10, 2020, filed under Item 5.07, Submission of Matters to a Vote of Security Holders. It states that a special meeting of stockholders of the company took place on November 10, 2020, with 24,473,002 shares entitled to vote and 21,118,690 shares present in person or by proxy, a quorum. The stockholders voted to amend the Certificate of Incorporation to increase authorized common stock from 30,000,000 shares to 60,000,000 shares. The results printed are 19,555,045 For, 1,537,217 Against and 26,428 Abstain. The signature block shows /s/ Joseph E. Payne, Chief Executive Officer, dated November 12, 2020.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event
reported): November 10, 2020

ARCTURUS
THERAPEUTICS HOLDINGS INC.

(Exact name of registrant as specified
in its charter)

Delaware | 001-38942 | 32-0595345
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.)

10628 Science Center Drive , Suite 250

San Diego , California 92121

(Address of principal executive offices)

Registrant’s telephone number,
including area code: (858) 900-2660

(Former name or former address, if changed
since last report)

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common stock, par value $0.001 per share | ARCT | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a
Vote of Security Holders.

On November 10, 2020, Arcturus Therapeutics
Holdings Inc. (the “Company”) held a special meeting of stockholders (the “Meeting”). The total number
of shares entitled to vote at the Meeting was 24,473,002 and there were present at the Meeting, in person or by proxy, 21,118,690
shares, which constituted a quorum for the Meeting.

At the Meeting, the stockholders voted to amend the Company’s
Certificate of Incorporation to increase the number of shares of common stock the Company is authorized to issue from 30,000,000
shares to 60,000,000 shares. The final results of the stockholder votes at the Meeting are set forth below:

For | Against | Abstain
19,555,045 | 1,537,217 | 26,428

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. | Description of Exhibit
104 | Cover Page to this Current Report on Form 8-K in Inline XBRL

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Arcturus Therapeutics Holdings Inc.
Date: November 12, 2020
By: | /s/ Joseph E. Payne
Name: | Joseph E. Payne
Title: | Chief Executive Officer

File and source

File

SEC_ARCT_8-K_filed2020-11-13_0001193805-20-001417.htm

Size

22,787 bytes

SHA-256

6a84e21d5894d5711b8312252640acad2658ce29bb742e9a9fc140cf59ee87dc

Our copy

SEC_ARCT_8-K_filed2020-11-13_0001193805-20-001417.htm

Original

www.sec.gov